Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo

Cancer Cell

Volumn 10, Issue 6, 2006, Pages 501-514

  Ringshausen, Ingo ^a   O'Shea, Clodagh C ^a   Finch, Andrew J ^a   Swigart, Lamorna Brown ^a   Evan, Gerard I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE REPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; RNA TRANSLATION; TUMOR CELL; WILD TYPE;

EID: 33845185824     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2006.10.010     Document Type: Article

References (57)

1. Alarcon R., Koumenis C., Geyer R.K., Maki C.G., and Giaccia A.J. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res. 59 (1999) 6046-6051
2. Bianco R., Ciardiello F., and Tortora G. Chemosensitization by antisense oligonucleotides targeting MDM2. Curr. Cancer Drug Targets 5 (2005) 51-56
3. Bode A.M., and Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4 (2004) 793-805
4. Boesten L.S., Zadelaar S.M., De Clercq S., Francoz S., van Nieuwkoop A., Biessen E.A., Hofmann F., Feil S., Feil R., Jochemsen A.G., et al. Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death. Cell Death Differ. 13 (2006) 2089-2098
5. Bottger A., Bottger V., Sparks A., Liu W.L., Howard S.F., and Lane D.P. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7 (1997) 860-869
6. Bouvard V., Zaitchouk T., Vacher M., Duthu A., Canivet M., Choisy-Rossi C., Nieruchalski M., and May E. Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice. Oncogene 19 (2000) 649-660
7. Brummelkamp T., Fabius A., Mullenders J., Madiredjo M., Velds A., Kerkhoven R., Bernards R., and Beijersbergen R. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat. Chem. Biol. 2 (2006) 202-206
8. Buolamwini J.K., Addo J., Kamath S., Patil S., Mason D., and Ores M. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. Curr. Cancer Drug Targets 5 (2005) 57-68
9. Chen D., Kon N., Li M., Zhang W., Qin J., and Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121 (2005) 1071-1083
10. Chen L., Yin H., Farooqi B., Sebti S., Hamilton A.D., and Chen J. p53 alpha-helix mimetics antagonize p53/MDM2 interaction and activate p53. Mol. Cancer Ther. 4 (2005) 1019-1025
11. Chene P., Fuchs J., Bohn J., Garcia-Echeverria C., Furet P., and Fabbro D. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. J. Mol. Biol. 299 (2000) 245-253
12. Chene P., Fuchs J., Carena I., Furet P., and Garcia-Echeverria C. Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells. FEBS Lett. 529 (2002) 293-297
13. Chipuk J.E., Bouchier-Hayes L., Kuwana T., Newmeyer D.D., and Green D.R. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309 (2005) 1732-1735
14. Christophorou M.A., Martin-Zanca D., Soucek L., Lawlor E.R., Brown-Swigart L., Verschuren E.W., and Evan G.I. Temporal dissection of p53 function in vitro and in vivo. Nat. Genet. 37 (2005) 718-726
15. Deb S.P. Cell cycle regulatory functions of the human oncoprotein MDM2. Mol. Cancer Res. 1 (2003) 1009-1016
16. Dornan D., Wertz I., Shimizu H., Arnott D., Frantz G.D., Dowd P., O'Rourke K., Koeppen H., and Dixit V.M. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429 (2004) 86-92
17. Dornan D., Shimizu H., Mah A., Dudhela T., Eby M., O'Rourke K., Seshagiri S., and Dixit V.M. ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage. Science 313 (2006) 1122-1126
18. Espinoza-Fonseca L.M. Targeting MDM2 by the small molecule RITA: Towards the development of new multi-target drugs against cancer. Theor. Biol. Med. Model 2 (2005) 38
19. Fei P., Bernhard E.J., and El-Deiry W.S. Tissue-specific induction of p53 targets in vivo. Cancer Res. 62 (2002) 7316-7327
20. Francoz S., Froment P., Bogaerts S., De Clercq S., Maetens M., Doumont G., Bellefroid E., and Marine J.C. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc. Natl. Acad. Sci. USA 103 (2006) 3232-3237
21. Ginzinger D.G. Gene quantification using real-time quantitative PCR: An emerging technology hits the mainstream. Exp. Hematol. 30 (2002) 503-512
22. Gu J., Kawai H., Nie L., Kitao H., Wiederschain D., Jochemsen A.G., Parant J., Lozano G., and Yuan Z.M. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J. Biol. Chem. 277 (2002) 19251-19254
23. Honda R., Tanaka H., and Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420 (1997) 25-27
24. Jones S., Roe A., Donehower L., and Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378 (1995) 206-208
25. Klein C., and Vassilev L.T. Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer 91 (2004) 1415-1419
26. Kubbutat M.H., Jones S.N., and Vousden K.H. Regulation of p53 stability by Mdm2. Nature 387 (1997) 299-303
27. Kulikov R., Winter M., and Blattner C. Binding of P53 to the central domain of MDM2 is regulated by phosphorylation. J. Biol. Chem. 281 (2006) 28575-28583
28. Leng R.P., Lin Y., Ma W., Wu H., Lemmers B., Chung S., Parant J.M., Lozano G., Hakem R., and Benchimol S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112 (2003) 779-791
29. Liu G., and Chen X. Regulation of the p53 transcriptional activity. J. Cell. Biochem. 97 (2006) 448-458
30. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
31. Ma J., Martin J.D., Zhang H., Auger K.R., Ho T.F., Kirkpatrick R.B., Grooms M.H., Johanson K.O., Tummino P.J., Copeland R.A., and Lai Z. A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination. Biochemistry 45 (2006) 9238-9245
32. Marine J.C., and Jochemsen A.G. Mdmx as an essential regulator of p53 activity. Biochem. Biophys. Res. Commun. 331 (2005) 750-760
33. Mendrysa S.M., McElwee M.K., Michalowski J., O'Leary K.A., Young K.M., and Perry M.E. mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol. Cell. Biol. 23 (2003) 462-472
34. Mendrysa S.M., O'Leary K., Mc A., Elwee M.K., Michalowski J., Eisenman R.N., Powell D.A., and Perry M.E. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev. 20 (2006) 16-21
35. Momand J., Zambetti G.P., Olson D.C., George D., and Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 (1992) 1237-1245
36. Montes de Oca Luna R., Wagner D., and Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378 (1995) 203-206
37. Parant J., Chavez-Reyes A., Little N.A., Yan W., Reinke V., Jochemsen A.G., and Lozano G. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet. 29 (2001) 92-95
38. Phillips D.H. Understanding the genotoxicity of tamoxifen?. Carcinogenesis 22 (2001) 839-849
39. Resnick-Silverman L., and Manfredi J.J. Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy. J. Cell Biochem. 99 (2006) 679-689
40. Robertson K.D., and Jones P.A. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol. Cell. Biol. 18 (1998) 6457-6473
41. Roth J., Dobbelstein M., Freedman D.A., Shenk T., and Levine A.J. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17 (1998) 554-564
42. Rubin P., and Casarett G.W. Clinical radiation pathology as applied to curative radiotherapy. Cancer 22 (1968) 767-778
43. Seoane J., Le H.V., and Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419 (2002) 729-734
44. Sluss H.K., Armata H., Gallant J., and Jones S.N. Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol. Cell. Biol. 24 (2004) 976-984
45. Thompson T., Tovar C., Yang H., Carvajal D., Vu B.T., Xu Q., Wahl G.M., Heimbrook D.C., and Vassilev L.T. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J. Biol. Chem. 279 (2004) 53015-53022 10.1074/jbc.M410233200 Published online October 6, 2004
46. Thut C.J., Goodrich J.A., and Tjian R. Repression of p53-mediated transcription by MDM2: A dual mechanism. Genes Dev. 11 (1997) 1974-1986
47. Toledo F., Krummel K.A., Lee C.J., Liu C.W., Rodewald L.W., Tang M., and Wahl G.M. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 9 (2006) 273-285
48. Tortora G., Caputo R., Damiano V., Bianco R., Chen J., Agrawal S., Bianco A.R., and Ciardiello F. A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. Int. J. Cancer 88 (2000) 804-809
49. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
50. -/- mouse embryo fibroblasts. Oncogene 13 (1996) 739-748
51. Wallace M., Worrall E., Pettersson S., Hupp T.R., and Ball K.L. Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol. Cell 23 (2006) 251-263
52. Wasylyk C., Salvi R., Argentini M., Dureuil C., Delumeau I., Abecassis J., Debussche L., and Wasylyk B. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 18 (1999) 1921-1934
53. Weber J.D., Jeffers J.R., Rehg J.E., Randle D.H., Lozano G., Roussel M.F., Sherr C.J., and Zambetti G.P. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev. 14 (2000) 2358-2365
54. Xiong S., Van Pelt C.S., Elizondo-Fraire A.C., Liu G., and Lozano G. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc. Natl. Acad. Sci. USA 103 (2006) 3226-3231
55. Yang Y., Ludwig R.L., Jensen J.P., Pierre S.A., Medaglia M.V., Davydov I.V., Safiran Y.J., Oberoi P., Kenten J.H., Phillips A.C., et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7 (2005) 547-559
56. Zhang Z., Wang H., Prasad G., Li M., Yu D., Bonner J.A., Agrawal S., and Zhang R. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin. Cancer Res. 10 (2004) 1263-1273
57. Zhong Q., Gao W., Du F., and Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121 (2005) 1085-1095